Literature DB >> 33971965

Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach.

Sarah K Royse1, Davneet S Minhas2, Brian J Lopresti2, Alice Murphy3, Tyler Ward3, Robert A Koeppe4, Santiago Bullich5, Susan DeSanti6, William J Jagust3, Susan M Landau3.   

Abstract

BACKGROUND: Inconsistent positivity thresholds, image analysis pipelines, and quantitative outcomes are key challenges of multisite studies using more than one β-amyloid (Aβ) radiotracer in positron emission tomography (PET). Variability related to these factors contributes to disagreement and lack of replicability in research and clinical trials. To address these problems and promote Aβ PET harmonization, we used [18F]florbetaben (FBB) and [18F]florbetapir (FBP) data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to derive (1) standardized Centiloid (CL) transformations and (2) internally consistent positivity thresholds based on separate young control samples.
METHODS: We analyzed Aβ PET data using a native-space, automated image processing pipeline that is used for PET quantification in many large, multisite AD studies and trials and made available to the research community. With this pipeline, we derived SUVR-to-CL transformations using the Global Alzheimer's Association Interactive Network data; we used reference regions for cross-sectional (whole cerebellum) and longitudinal (subcortical white matter, brain stem, whole cerebellum) analyses. Finally, we developed a FBB positivity threshold using an independent young control sample (N=62) with methods parallel to our existing FBP positivity threshold and validated the FBB threshold using a data-driven approach in ADNI participants (N=295).
RESULTS: The FBB threshold based on the young sample (1.08; 18 CL) was consistent with that of the data-driven approach (1.10; 21 CL), and the existing FBP threshold converted to CL with the derived transformation (1.11; 20 CL). The following equations can be used to convert whole cerebellum- (cross-sectional) and composite- (longitudinal) normalized FBB and FBP data quantified with the native-space pipeline to CL units: [18F]FBB: CLwhole cerebellum = 157.15 × SUVRFBB - 151.87; threshold=1.08, 18 CL [18F]FBP: CLwhole cerebellum = 188.22 × SUVRFBP - 189.16; threshold=1.11, 20 CL [18F]FBB: CLcomposite = 244.20 × SUVRFBB - 170.80 [18F]FBP: CLcomposite = 300.66 × SUVRFBP - 208.84
CONCLUSIONS: FBB and FBP positivity thresholds derived from independent young control samples and quantified using an automated, native-space approach result in similar CL values. These findings are applicable to thousands of available and anticipated outcomes analyzed using this pipeline and shared with the scientific community. This work demonstrates the feasibility of harmonized PET acquisition and analysis in multisite PET studies and internal consistency of positivity thresholds in standardized units.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid imaging; Beta-amyloid; Centiloid; Florbetaben; Florbetapir; Standardization

Year:  2021        PMID: 33971965     DOI: 10.1186/s13195-021-00836-1

Source DB:  PubMed          Journal:  Alzheimers Res Ther            Impact factor:   6.982


  21 in total

Review 1.  The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.

Authors:  Mark E Schmidt; Ping Chiao; Gregory Klein; Dawn Matthews; Lennart Thurfjell; Patricia E Cole; Richard Margolin; Susan Landau; Norman L Foster; N Scott Mason; Susan De Santi; Joyce Suhy; Robert A Koeppe; William Jagust
Journal:  Alzheimers Dement       Date:  2014-11-24       Impact factor: 21.566

2.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

3.  Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.

Authors:  Susan M Landau; Allison Fero; Suzanne L Baker; Robert Koeppe; Mark Mintun; Kewei Chen; Eric M Reiman; William J Jagust
Journal:  J Nucl Med       Date:  2015-03-05       Impact factor: 10.057

4.  The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Authors:  William E Klunk; Robert A Koeppe; Julie C Price; Tammie L Benzinger; Michael D Devous; William J Jagust; Keith A Johnson; Chester A Mathis; Davneet Minhas; Michael J Pontecorvo; Christopher C Rowe; Daniel M Skovronsky; Mark A Mintun
Journal:  Alzheimers Dement       Date:  2014-10-28       Impact factor: 21.566

5.  Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction.

Authors:  Matthias Brendel; Marcus Högenauer; Andreas Delker; Julia Sauerbeck; Peter Bartenstein; John Seibyl; Axel Rominger
Journal:  Neuroimage       Date:  2014-12-04       Impact factor: 6.556

6.  Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

Authors:  Nelleke Tolboom; Maqsood Yaqub; Ronald Boellaard; Gert Luurtsema; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-22       Impact factor: 9.236

7.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

8.  Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale.

Authors:  Michael Navitsky; Abhinay D Joshi; Ian Kennedy; William E Klunk; Christopher C Rowe; Dean F Wong; Michael J Pontecorvo; Mark A Mintun; Michael D Devous
Journal:  Alzheimers Dement       Date:  2018-07-11       Impact factor: 21.566

9.  Research and standardization in Alzheimer's trials: reaching international consensus.

Authors:  Maria C Carrillo; Christopher C Rowe; Cassandra Szoeke; Colin L Masters; David Ames; Tim O'Meara; S Lance Macaulay; Andrew Milner; Kathryn A Ellis; Paul Maruff; Stephanie R Rainey-Smith; Ralph N Martins; Lisa J Bain; Richard J Head
Journal:  Alzheimers Dement       Date:  2012-12-23       Impact factor: 21.566

10.  18F-Florbetaben PET beta-amyloid binding expressed in Centiloids.

Authors:  Christopher C Rowe; Vincent Doré; Gareth Jones; David Baxendale; Rachel S Mulligan; Santiago Bullich; Andrew W Stephens; Susan De Santi; Colin L Masters; Ludger Dinkelborg; Victor L Villemagne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-22       Impact factor: 9.236

View more
  8 in total

1.  β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3.

Authors:  Pierrick Bourgeat; Vincent Doré; Samantha C Burnham; Tammie Benzinger; Duygu Tosun; Shenpeng Li; Manu Goyal; Pamela LaMontagne; Liang Jin; Christopher C Rowe; Michael W Weiner; John C Morris; Colin L Masters; Jurgen Fripp; Victor L Villemagne
Journal:  Neuroimage       Date:  2022-07-30       Impact factor: 7.400

2.  Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer's disease: a multicenter study.

Authors:  Hiroshi Matsuda; Kyoji Okita; Yumiko Motoi; Toshiki Mizuno; Manabu Ikeda; Nobuo Sanjo; Koji Murakami; Taiki Kambe; Toshiki Takayama; Kei Yamada; Takashi Suehiro; Keiko Matsunaga; Takanori Yokota; Ukihide Tateishi; Yoko Shigemoto; Yukio Kimura; Emiko Chiba; Takahiro Kawashima; Yui Tomo; Hisateru Tachimori; Yuichi Kimura; Noriko Sato
Journal:  Ann Nucl Med       Date:  2022-10-04       Impact factor: 2.258

3.  Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier.

Authors:  Dawn C Matthews; Ana S Lukic; Randolph D Andrews; Miles N Wernick; Stephen C Strother; Mark E Schmidt
Journal:  Alzheimers Dement (N Y)       Date:  2022-07-08

4.  A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease.

Authors:  Wagner S Brum; Marco Antônio de Bastiani; Andrei Bieger; Joseph Therriault; João P Ferrari-Souza; Andréa L Benedet; Paramita Saha-Chaudhuri; Diogo O Souza; Nicholas J Ashton; Henrik Zetterberg; Tharick A Pascoal; Thomas Karikari; Kaj Blennow; Pedro Rosa-Neto; Eduardo R Zimmer
Journal:  Alzheimers Dement (N Y)       Date:  2022-03-13

5.  The accuracy and robustness of plasma biomarker models for amyloid PET positivity.

Authors:  Andréa L Benedet; Wagner S Brum; Oskar Hansson; Thomas K Karikari; Eduardo R Zimmer; Henrik Zetterberg; Kaj Blennow; Nicholas J Ashton
Journal:  Alzheimers Res Ther       Date:  2022-02-07       Impact factor: 6.982

Review 6.  Quantification of amyloid PET for future clinical use: a state-of-the-art review.

Authors:  Hugh G Pemberton; Lyduine E Collij; Fiona Heeman; Ariane Bollack; Mahnaz Shekari; Gemma Salvadó; Isadora Lopes Alves; David Vallez Garcia; Mark Battle; Christopher Buckley; Andrew W Stephens; Santiago Bullich; Valentina Garibotto; Frederik Barkhof; Juan Domingo Gispert; Gill Farrar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-07       Impact factor: 10.057

7.  Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint.

Authors:  Kelsey R Thomas; Alexandra J Weigand; Lauren C Edwards; Emily C Edmonds; Katherine J Bangen; Gema Ortiz; Kayla S Walker; Mark W Bondi
Journal:  Alzheimers Res Ther       Date:  2022-08-22       Impact factor: 8.823

8.  Predicting conversion of brain β-amyloid positivity in amyloid-negative individuals.

Authors:  Chae Jung Park; Younghoon Seo; Yeong Sim Choe; Hyemin Jang; Hyejoo Lee; Jun Pyo Kim
Journal:  Alzheimers Res Ther       Date:  2022-09-12       Impact factor: 8.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.